Bajaj Healthcare gets EIR from USFDA for API manufacturing facility in Gujarat

14 Sep 2023 Evaluate

Bajaj Healthcare has received Establishment Inspection Report (EIR) from the United State Food and Drug Administration (USFDA), for the Pre-approval inspection that was carried out by the USFDA in November, 2022 at its API manufacturing facility in Savli, Vadodara, Gujarat, with Zero 483 observations (No inspectional observations).

The receipt of the Establishment Inspection Report signifies the successful conclusion of the inspection. It serves as a testament to its dedication to upholding global standards of quality and compliance

Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.

Bajaj Healthcare Share Price

559.00 89.90 (19.16%)
18-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1800.30
Dr. Reddys Lab 1275.05
Cipla 1472.05
Lupin 2098.70
Zydus Lifesciences 979.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.